Feb 13th 2013 - Edison Investment Research today published a report on quickview entitled "DSC127 Starts Phase III". In summary, the report says:
Enrolment for Derma Sciences lead candidate DSC127 has just started for the first of two Phase III studies in non-healing diabetic foot ulcers (DFUs), a $900m market. While long term investment returns will be tied heavily to Phase III results, the robust Phase II separation versus vehicle adds confidence, and Derma Sciences’ growing operating wound care products business also provides downside protection.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »